Chronic Liver Disease in Europe: A Preventable Crisis Going Undetected

Why It Matters

The rising burden threatens economic productivity and strains health systems, while early detection could avert costly advanced disease.

Key Takeaways

• MASLD affects ~33% of EU and UK populations.
• Alcohol causes ~40% of 287,000 premature liver deaths annually.
• Liver disease now second to heart disease in working‑life years lost.
• Early, non‑invasive fibrosis testing could cut progression to cirrhosis.
• Coordinated policies linking liver health with diabetes, obesity, and alcohol needed.

Pulse Analysis

Europe is confronting a silent epidemic of chronic liver disease that rivals cardiovascular conditions in its impact on the workforce. Recent analysis by the Barcelona Institute for Global Health, published in The Lancet Regional Health—Europe, estimates that one in three adults in the EU and United Kingdom now live with metabolic dysfunction‑associated steatotic liver disease (MASLD), a condition that accelerates the risk of liver cancer. Compounding the metabolic surge, the continent records the world’s highest per‑capita alcohol consumption, with alcohol responsible for roughly 40 % of the 287,000 premature liver‑related deaths each year.

The authors argue that the current hepatology‑centric model is insufficient; instead, liver health must be woven into broader non‑communicable disease strategies. Primary‑care physicians are urged to adopt routine, non‑invasive fibrosis assessments alongside blood pressure and cholesterol checks, enabling earlier identification of at‑risk patients. Such screening, combined with robust surveillance systems, could halt progression to cirrhosis and cancer, reducing the long‑term cost burden on hospitals and specialty clinics. Aligning liver‑focused interventions with diabetes, obesity, and cardiovascular programs also maximizes resource efficiency.

From an economic standpoint, premature liver mortality erodes productivity, costing European economies billions in lost labor and health‑care expenditures. Policymakers therefore face a clear mandate: tighten alcohol regulations, curb ultraprocessed food marketing, and fund harm‑reduction services while dismantling the stigma that discourages care‑seeking. By treating liver disease as a shared public‑health responsibility rather than an individual failing, Europe can transform a preventable crisis into a model for integrated disease prevention. The series’ recommendations offer a roadmap that, if acted upon before advanced disease becomes the norm, could safeguard the health of future generations.